Clinical Trial: Comparative Efficacy and Safety of First-Line Targeted Therapies for Advanced Non-Small-Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials (Japan)

Tokyo, Oct. 21 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000063348) titled 'Comparative efficacy and safety of first-line treatments for advanced EGFR exon 20 insertion-mutated non-small-cell lung cancer: a systematic review and network meta-analysis of randomized controlled trials' on Oct. 20.

Study Type: Others,meta-analysis etc

Primary Sponsor: Institute - Yokohama City University

Condition: Condition - Unresectable locally advanced or metastatic non-small-cell lung cancer harboring EGFR exon 20 insertion mutations Classification by malignancy - Malignancy Genomic information - NO

Objective: Narrative objectives1 - To compare the efficacy and safety of first-line targeted monotherapy or targeted therapy plus platinum-pemetrexed chemotherapy versus platinum-pemetrexed chemotherapy in adults with previously untreated advanced NSCLC harboring EGFR exon 20 insertion mutations, through a systematic review and network meta-analysis of randomized controlled trials. The primary outcome is progression-free survival. Basic objectives2 - Safety,Efficacy

Eligibility: Age-lower limit - 18 years-old =18 years with untreated advanced EGFR exon 20 insertion-mutated NSCLC, comparing targeted monotherapy or targeted therapy plus platinum-pemetrexed with eligible first-line regimens. Mixed cohorts require extractable randomized subgroup data. Papers, abstracts, registry and sponsor results require verifiable randomized numeric comparisons. All eligible trials will be included; abstract/sponsor-only reports will be excluded in sensitivity analysis. Key exclusion criteria - Trials exclusively in previously treated advanced disease; nonrandomized comparative studies, single-arm studies, observational studies, case series, reviews, and studies without extractable randomized comparative data for the eligible mutation population. Multiple reports of the same trial will be linked and never counted as separate trials.

Recruitment Status: Recruitment status - No longer recruiting Date of protocol fixation - 2026 Year 08 Month 20 Day Date of IRB - 2026 Year 07 Month 05 Day Anticipated trial start date - 2026 Year 10 Month 20 Day Last follow-up date - 2026 Year 12 Month 20 Day

To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000072512

Disclaimer: Curated by HT Syndication.